Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 6/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.39 |
| ▸ | TYK2 | P29597 | 5/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.32 |
| ▸ | FYN | P06241 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3314987 | 0.89 | CSNK2A2 (0.39) | CSNK2A2CSNK2A1TYK2STAT3EGLN2 | |
| SCHEMBL3313276 | 0.87 | CSNK2A2 (0.39) | CSNK2A2CSNK2A1TYK2STAT3EGLN2 | |
| SCHEMBL2309014 | 0.87 | TYK2 (0.51) | CSNK2A2CSNK2A1TYK2STAT3EGLN2 | |
| SCHEMBL13641662 | 0.79 | TYK2 (0.39) | CSNK2A2CSNK2A1TYK2STAT3IRAK4 | |
| SCHEMBL3313469 | 0.78 | CSNK2A2 (0.42) | CSNK2A2CSNK2A1TYK2DYRK1AFGFR4 | |
| SCHEMBL13644218 | 0.78 | CSNK2A2 (0.41) | CSNK2A2TYK2DYRK1AFGFR4 | |
| SCHEMBL13422007 | 0.77 | TYK2 (0.52) | CSNK2A2TYK2STAT3EGLN2DYRK1A | |
| SCHEMBL12013157 | 0.77 | TYK2 (0.53) | CSNK2A2CSNK2A1TYK2STAT3PDE4D | |
| SCHEMBL2357295 | 0.77 | CSNK2A2 (0.41) | CSNK2A2CSNK2A1TYK2EGLN2DYRK1A | |
| SCHEMBL13641453 | 0.76 | TYK2 (0.53) | CSNK2A2CSNK2A1TYK2STAT3IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252795-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | CSNK2A2 135/4885CSNK2A1 88/4885TYK2 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.